Willow Historical Income Statement

WLLW Stock

CAD 0.04 0.01 14.29%

Historical analysis of Willow Biosciences income statement accounts such as Interest Expense of 171.5 K, Selling And Marketing Expenses of 20.8 K, Other Operating Expenses of 17.7 M or Total Operating Expenses of 15.5 M can show how well Willow Biosciences performed in making a profits. Evaluating Willow Biosciences income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Willow Biosciences's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Willow Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Willow Biosciences is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Willow Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Willow Income Statement Analysis

Willow Biosciences Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Willow Biosciences shareholders. The income statement also shows Willow investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Willow Biosciences Income Statement Chart

At this time, Willow Biosciences' Total Revenue is very stable compared to the past year. As of the 3rd of March 2025, Reconciled Depreciation is likely to grow to about 2.1 M, while Selling And Marketing Expenses is likely to drop about 20.8 K.

Selling And Marketing Expenses Other Operating Expenses Total Operating Expenses Selling General Administrative

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Willow Biosciences. It is also known as Willow Biosciences overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Willow Biosciences' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Willow Biosciences current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Willow Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Willow Biosciences income statement Correlations

	Interest Expense	Selling And Marketing Expenses	Other Operating Expenses	Operating Income	Ebit	Ebitda	Total Operating Expenses	Net Income	Income Tax Expense	Selling General Administrative	Depreciation And Amortization	Income Before Tax	Total Other Income Expense Net	Gross Profit	Cost Of Revenue	Net Interest Income	Interest Income	Net Income From Continuing Ops	Research Development	Tax Provision	Reconciled Depreciation
Interest Expense		-0.19	0.62	-0.3	-0.48	-0.49	0.55	-0.3	-0.3	0.62	0.52	-0.3	0.11	0.02	-0.26	0.33	0.56	-0.13	0.59	0.68	-0.36
Selling And Marketing Expenses	-0.19		0.5	-0.67	-0.6	-0.6	0.56	-0.58	-0.41	0.52	0.57	-0.58	-0.31	-0.51	0.71	0.55	0.43	-0.63	0.42	0.3	0.7
Other Operating Expenses	0.62	0.5		-0.74	-0.98	-0.98	1.0	-0.58	-0.51	0.97	0.97	-0.58	0.18	-0.64	0.2	0.89	0.91	-0.35	0.97	0.92	0.41
Operating Income	-0.3	-0.67	-0.74		0.78	0.77	-0.76	0.91	0.78	-0.85	-0.79	0.92	0.31	0.36	-0.39	-0.55	-0.5	0.65	-0.59	-0.46	-0.36
Ebit	-0.48	-0.6	-0.98	0.78		1.0	-0.99	0.62	0.52	-0.95	-0.97	0.61	-0.16	0.69	-0.28	-0.91	-0.89	0.39	-0.95	-0.87	-0.53
Ebitda	-0.49	-0.6	-0.98	0.77	1.0		-0.99	0.6	0.51	-0.95	-0.97	0.59	-0.17	0.71	-0.26	-0.92	-0.9	0.38	-0.96	-0.87	-0.52
Total Operating Expenses	0.55	0.56	1.0	-0.76	-0.99	-0.99		-0.6	-0.51	0.96	0.98	-0.59	0.17	-0.67	0.24	0.91	0.9	-0.37	0.96	0.9	0.48
Net Income	-0.3	-0.58	-0.58	0.91	0.62	0.6	-0.6		0.71	-0.72	-0.69	1.0	0.48	0.01	-0.35	-0.28	-0.28	0.72	-0.42	-0.39	-0.28
Income Tax Expense	-0.3	-0.41	-0.51	0.78	0.52	0.51	-0.51	0.71		-0.63	-0.53	0.71	0.5	0.13	-0.07	-0.35	-0.3	0.7	-0.36	-0.26	-0.07
Selling General Administrative	0.62	0.52	0.97	-0.85	-0.95	-0.95	0.96	-0.72	-0.63		0.95	-0.72	0.02	-0.53	0.21	0.8	0.82	-0.46	0.88	0.82	0.31
Depreciation And Amortization	0.52	0.57	0.97	-0.79	-0.97	-0.97	0.98	-0.69	-0.53	0.95		-0.68	0.11	-0.58	0.3	0.83	0.83	-0.42	0.93	0.88	0.52
Income Before Tax	-0.3	-0.58	-0.58	0.92	0.61	0.59	-0.59	1.0	0.71	-0.72	-0.68		0.49	0.01	-0.35	-0.27	-0.27	0.73	-0.41	-0.37	-0.27
Total Other Income Expense Net	0.11	-0.31	0.18	0.31	-0.16	-0.17	0.17	0.48	0.5	0.02	0.11	0.49		-0.49	-0.33	0.33	0.36	0.83	0.35	0.34	0.18
Gross Profit	0.02	-0.51	-0.64	0.36	0.69	0.71	-0.67	0.01	0.13	-0.53	-0.58	0.01	-0.49		-0.26	-0.9	-0.75	-0.07	-0.7	-0.51	-0.63
Cost Of Revenue	-0.26	0.71	0.2	-0.39	-0.28	-0.26	0.24	-0.35	-0.07	0.21	0.3	-0.35	-0.33	-0.26		0.25	0.17	-0.48	0.15	0.05	0.47
Net Interest Income	0.33	0.55	0.89	-0.55	-0.91	-0.92	0.91	-0.28	-0.35	0.8	0.83	-0.27	0.33	-0.9	0.25		0.93	-0.21	0.92	0.8	0.55
Interest Income	0.56	0.43	0.91	-0.5	-0.89	-0.9	0.9	-0.28	-0.3	0.82	0.83	-0.27	0.36	-0.75	0.17	0.93		-0.17	0.96	0.89	0.33
Net Income From Continuing Ops	-0.13	-0.63	-0.35	0.65	0.39	0.38	-0.37	0.72	0.7	-0.46	-0.42	0.73	0.83	-0.07	-0.48	-0.21	-0.17		-0.21	-0.19	-0.18
Research Development	0.59	0.42	0.97	-0.59	-0.95	-0.96	0.96	-0.42	-0.36	0.88	0.93	-0.41	0.35	-0.7	0.15	0.92	0.96	-0.21		0.95	0.44
Tax Provision	0.68	0.3	0.92	-0.46	-0.87	-0.87	0.9	-0.39	-0.26	0.82	0.88	-0.37	0.34	-0.51	0.05	0.8	0.89	-0.19	0.95		0.35
Reconciled Depreciation	-0.36	0.7	0.41	-0.36	-0.53	-0.52	0.48	-0.28	-0.07	0.31	0.52	-0.27	0.18	-0.63	0.47	0.55	0.33	-0.18	0.44	0.35

Click cells to compare fundamentals

Willow Biosciences Account Relationship Matchups

Willow Biosciences income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Interest Expense	40K	27K	26K	142K	163.3K	171.5K
Other Operating Expenses	16.9M	23.3M	19.2M	14.6M	16.8M	17.7M
Operating Income	(23.1M)	(23.3M)	(18.4M)	(13.5M)	(12.1M)	(11.5M)
Ebit	(16.7M)	(22.8M)	(18.1M)	(13.5M)	(12.1M)	(11.5M)
Ebitda	(13.5M)	(19.6M)	(15.5M)	(11.6M)	(10.5M)	(9.9M)
Total Operating Expenses	16.9M	23.3M	19.2M	12.8M	14.7M	15.5M
Net Income	(34.0M)	(6.2M)	(14.8M)	(13.0M)	(11.7M)	(11.1M)
Income Tax Expense	40K	27K	53K	(5K)	(5.8K)	(5.5K)
Selling General Administrative	6.4M	7.8M	8.3M	6.0M	6.9M	7.3M
Depreciation And Amortization	3.2M	3.2M	2.6M	1.8M	2.1M	2.2M
Income Before Tax	(33.9M)	(6.1M)	(14.8M)	(13.0M)	(11.7M)	(11.1M)
Total Other Income Expense Net	(10.9M)	17.2M	3.6M	424K	381.6K	400.7K
Gross Profit	10K	(11.4M)	(6.7M)	(659K)	(593.1K)	(622.8K)
Net Interest Income	115K	387K	274K	125K	143.8K	129.5K
Interest Income	155K	414K	300K	267K	307.1K	176.0K
Total Revenue	10K	133K	821K	1.2M	1.3M	1.4M
Net Income From Continuing Ops	(33.9M)	(6.1M)	(14.8M)	(13.0M)	(11.7M)	(12.3M)
Net Income Applicable To Common Shares	(44.6M)	(33.9M)	(6.1M)	(14.8M)	(13.3M)	(14.0M)
Research Development	7.3M	11.5M	7.5M	6.8M	7.8M	6.6M
Tax Provision	179K	0.0	53K	(5K)	(5.8K)	(6.0K)
Reconciled Depreciation	3.2M	3.2M	2.6M	1.8M	1.6M	2.1M

Pair Trading with Willow Biosciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Willow Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Willow Biosciences will appreciate offsetting losses from the drop in the long position's value.

Moving against Willow Stock

0.77	TD	Toronto Dominion Bank	Pair Corr
0.72	JPM	JPMorgan Chase	Pair Corr
0.48	CAE	CAE Inc	Pair Corr
0.44	GOOG	Alphabet CDR	Pair Corr
0.33	SOU	Southern Energy Corp	Pair Corr

The ability to find closely correlated positions to Willow Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Willow Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Willow Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Willow Biosciences to buy it.

The correlation of Willow Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Willow Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Willow Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Willow Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Other Information on Investing in Willow Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Willow Historical Income Statement

About Willow Income Statement Analysis

Willow Biosciences Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Willow Biosciences income statement Correlations

Willow Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Willow Biosciences income statement Accounts

Pair Trading with Willow Biosciences

Moving against Willow Stock

Other Information on Investing in Willow Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebitda	+ 1.0	Ebit
Income Before Tax	+ 1.0	Net Income
Depreciation And Amortization	+ 0.98	Total Operating Expenses
Selling General Administrative	+ 0.97	Other Operating Expenses
Depreciation And Amortization	+ 0.97	Other Operating Expenses

Total Operating Expenses	- 0.99	Ebitda
Total Operating Expenses	- 0.99	Ebit
Ebitda	- 0.98	Other Operating Expenses
Ebit	- 0.98	Other Operating Expenses
Depreciation And Amortization	- 0.97	Ebitda
Depreciation And Amortization	- 0.97	Ebit